Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie $
LC said
Nov 13, 2014
Isiscat2011 wrote:
Speaking of costs, an 8 week duration of Harvoni only costs 63K (did I just say only?). That may be in the same ballpark as 12 weeks of Abbvie. So, the 8 weekers may actually stand the best chance of getting Harvoni. In the longer term Gilead's new Harvoni + 1 will only be 6 weeks duration and cost predictions are ~the same cost of 8 weeks of Harvoni.
Could be the longer duration patients end up having the hardest time getting the Harvoni, once Abbive is approved, at least in the short term. That kinda sucks because the side effects for Abbvie + Riba over a 24 week course could get pretty rough. Just speculating.
Maybe, but as sneaky as AbbVie has shown themselves to be, with the patents and the tax situation, I doubt they are going to let Gilead steal a march on them with something so simple. Even though they can't sale Harvoni themselves, they want to try and make Gilead pay them royalties on it! I must hand it to AbbVie's patent lawyers. I do wish I had some extra money to play the market.
Isiscat2011 said
Nov 13, 2014
LC wrote:
Maybe AbbVie will sale it too, eventually. No wonder they "weren't interested in getting into a price war". Haha on Gilead, it couldn't happen to a more deserving company.
Speaking of costs, an 8 week duration of Harvoni only costs 63K (did I just say only?). That may be in the same ballpark as 12 weeks of Abbvie. So, the 8 weekers may actually stand the best chance of getting Harvoni. In the longer term Gilead's new Harvoni + 1 will only be 6 weeks duration and cost predictions are ~the same cost of 8 weeks of Harvoni.
Could be the longer duration patients end up having the hardest time getting the Harvoni, once Abbive is approved, at least in the short term. That kinda sucks because the side effects for Abbvie + Riba over a 24 week course could get pretty rough. Just speculating.
LC said
Nov 13, 2014
Maybe AbbVie will sale it too, eventually. No wonder they "weren't interested in getting into a price war". Haha on Gilead, it couldn't happen to a more deserving company.
Tess said
Nov 13, 2014
Thanks Isiscat. That is encouraging! Unfortunately pricing is exorbitant but I am hoping for insurance coverage.
Isiscat2011 said
Nov 13, 2014
Tess wrote:
Will this affect the availability of Harvoni?
This is just more fighting over $$ that goes on within the Pharma industry. Litigation costs are already built into the exhorbitant drug prices so it shouldn't have much impact, IMO.
Abbvie's pricing, along with more HCV txs being FDA approved, will have the greatest impact on cost/availability of Harvoni but I would not expect to see dramatic price reductions right away. Tx duration will be a significant factor because shorter tx = lower cost.
This is assuming that Congress doesn't step in with price controls, which is a safe assumption, particularly given the GOP's dominance in Congress.
Tess said
Nov 12, 2014
Will this affect the availability of Harvoni?
Matt Chris said
Nov 12, 2014
Hey All
AbbVie has been granted five US patents that specifically claim the use of Sofosbuvir and Ledipasvir, the drug combination that Gilead sales under the name of Harvoni.
Check out the article Seeking alpha - http://www.seekingalpha.com/article/2674915
This will takes years of litigation to sort out and in the end the provisonal patents that were filed long ago will figure in the end result.
Maybe, but as sneaky as AbbVie has shown themselves to be, with the patents and the tax situation, I doubt they are going to let Gilead steal a march on them with something so simple. Even though they can't sale Harvoni themselves, they want to try and make Gilead pay them royalties on it!
I must hand it to AbbVie's patent lawyers. I do wish I had some extra money to play the market.
Speaking of costs, an 8 week duration of Harvoni only costs 63K (did I just say only?). That may be in the same ballpark as 12 weeks of Abbvie. So, the 8 weekers may actually stand the best chance of getting Harvoni. In the longer term Gilead's new Harvoni + 1 will only be 6 weeks duration and cost predictions are ~the same cost of 8 weeks of Harvoni.
Could be the longer duration patients end up having the hardest time getting the Harvoni, once Abbive is approved, at least in the short term. That kinda sucks because the side effects for Abbvie + Riba over a 24 week course could get pretty rough. Just speculating.
Thanks Isiscat. That is encouraging! Unfortunately pricing is exorbitant but I am hoping for insurance coverage.
This is just more fighting over $$ that goes on within the Pharma industry. Litigation costs are already built into the exhorbitant drug prices so it shouldn't have much impact, IMO.
Abbvie's pricing, along with more HCV txs being FDA approved, will have the greatest impact on cost/availability of Harvoni but I would not expect to see dramatic price reductions right away. Tx duration will be a significant factor because shorter tx = lower cost.
This is assuming that Congress doesn't step in with price controls, which is a safe assumption, particularly given the GOP's dominance in Congress.
Will this affect the availability of Harvoni?
Hey All
AbbVie has been granted five US patents that specifically claim the use of Sofosbuvir and Ledipasvir, the drug combination that Gilead sales under the name of Harvoni.
Check out the article Seeking alpha - http://www.seekingalpha.com/article/2674915
This will takes years of litigation to sort out and in the end the provisonal patents that were filed long ago will figure in the end result.
matt